A Short Delay Is Still Bad News for AbbVie
The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. On the surface, a three-month delay isn't...
The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. On the surface, a three-month delay isn't...
U.S. stocks traded mostly higher on Tuesday after a March inflation report turned out not as bad as some traders...
LAS VEGAS -- ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a global brand management holdings company with commercial...
SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF)-backed Chinese ride-hailing company, Didi Chuxing, also known as the Uber of China, raised $1.5 billion debt...
Key benchmarks on both sides of the Atlantic hit record highs at the end of last week A stock market...
It seems like we are in a period of time where many of us are not wishing to play by...
Hopes for a strong recovery in EM currencies persist — just about When French investment bank Natixis polled its clients...
DHT (NYSE:DHT) was downgraded by investment analysts at DNB Markets from a "buy" rating to a "hold" rating in a research...
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about...
Euronav (NYSE:EURN) was downgraded by equities research analysts at ING Group from a "buy" rating to a "hold" rating in...
Get breaking news delivered straight into your inbox
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Rotten Tomato stocks is a wholly-owned subsidiary of Grainne Capital Limited.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
© Copyright 2023 RottenTomatoStocks. All Rights Reserved